Tenax Therapeutics, Inc. TENX
We take great care to ensure that the data presented and summarized in this overview for TENAX THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in TENX
Top Purchases
Top Sells
About TENX
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Insider Transactions at TENX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 08
2024
|
Michael H. Davidson |
BUY
Open market or private purchase
|
Direct |
2,500
+46.46%
|
-
|
|
Aug 08
2024
|
Gerald T Proehl |
BUY
Open market or private purchase
|
Direct |
1,666
+49.99%
|
-
|
|
Sep 21
2022
|
Stuart Rich Chief Medical Officer |
BUY
Bona fide gift
|
Indirect |
1,909,585
+50.0%
|
-
|
|
Sep 21
2022
|
Stuart Rich Chief Medical Officer |
SELL
Bona fide gift
|
Direct |
1,909,585
-81.82%
|
-
|
|
Aug 11
2022
|
Declan Doogan |
BUY
Bona fide gift
|
Direct |
567,871
+13.5%
|
-
|
|
Aug 11
2022
|
Declan Doogan |
SELL
Bona fide gift
|
Indirect |
567,871
-100.0%
|
-
|
|
Nov 29
2021
|
Stuart Rich Chief Medical Officer |
BUY
Bona fide gift
|
Indirect |
1,909,585
+50.0%
|
-
|
|
Nov 29
2021
|
Stuart Rich Chief Medical Officer |
SELL
Bona fide gift
|
Indirect |
1,909,585
-100.0%
|
-
|
|
Oct 12
2021
|
Stuart Rich Chief Medical Officer |
BUY
Bona fide gift
|
Indirect |
1,909,585
+50.0%
|
-
|
|
Oct 12
2021
|
Stuart Rich Chief Medical Officer |
SELL
Bona fide gift
|
Direct |
1,909,585
-45.0%
|
-
|
|
Jun 30
2021
|
Declan Doogan |
SELL
Bona fide gift
|
Direct |
567,871
-18.5%
|
-
|
|
Jun 11
2021
|
Michael H. Davidson |
BUY
Grant, award, or other acquisition
|
Direct |
512,000
+45.77%
|
-
|
|
Jun 11
2021
|
Stuart Rich Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,581,000
+45.77%
|
-
|
|
Jun 11
2021
|
Declan Doogan |
BUY
Exercise of conversion of derivative security
|
Direct |
3,070,000
+45.77%
|
-
|
|
Jan 15
2021
|
Stuart Rich Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,581
+50.0%
|
-
|
|
Jan 15
2021
|
Stuart Rich Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
662,517
+50.0%
|
-
|
|
Sep 08
2020
|
Armistice Capital, LLC Director |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Sep 08
2020
|
Armistice Capital, LLC Director |
BUY
Open market or private purchase
|
Direct |
8,543
+0.42%
|
$8,543
$1.46 P/Share
|
|
Sep 04
2020
|
Armistice Capital, LLC Director |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Sep 04
2020
|
Armistice Capital, LLC Director |
BUY
Open market or private purchase
|
Direct |
23,457
+1.15%
|
$23,457
$1.41 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 4.17K shares |
|---|